Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study

OBJECTIVES: Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia. The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-dose pharmacodynamics, pharmacokinetics and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiramoto, Masanari, Liu, Sha, Shen, Zancong, Yan, Xiaohong, Yamamoto, Amy, Gillen, Michael, Ito, Yasushi, Hall, Jesse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105922/
https://www.ncbi.nlm.nih.gov/pubmed/29868853
http://dx.doi.org/10.1093/rheumatology/key100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105922/
https://www.ncbi.nlm.nih.gov/pubmed/29868853
http://dx.doi.org/10.1093/rheumatology/key100

Ejemplares similares